Business Context and Reporting Period
This Form 8-K was filed by PharmAthene, Inc. (not Altimmune, Inc.) on February 22, 2010. The report details a material definitive agreement entered into on the same date regarding the advanced development of SparVax, a second-generation recombinant protective antigen anthrax vaccine intended for the U.S. Strategic National Stockpile.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for the reporting period. The document focuses exclusively on the terms of a specific government contract modification.
- Contract Base Funding: Up to approximately $61 million on a cost-reimbursement-plus-fixed-fee basis through December 31, 2012, contingent on milestone achievement.
- Contract Options: Up to an additional $17 million if the government exercises three available options.
- Historical Context: A prior $13.9 million contract for Valortim was awarded in September 2007.
Material Changes
The primary material change is the amendment of the existing research and development contract with the U.S. Department of Health and Human Services (HHS) via BARDA. This modification extends the performance period through December 31, 2012, and increases the potential funding ceiling for the SparVax program.
Outlook, Risks, and Contingencies
Future funding is contingent upon the achievement of specific milestones and the government's sole discretion to exercise contract options. The filing notes that the $61 million base amount and the $17 million in option amounts are potential maximums, not guaranteed payments. No other risks or unusual items are detailed in this specific report.
Investor Verification Checklist
- Verify the current status of SparVax development milestones to assess the likelihood of receiving the full $61 million base funding.
- Confirm whether the government has exercised any of the three $17 million contract options.
- Review subsequent filings to determine if the company has generated actual revenue from this contract or if it remains in the development phase.
- Clarify the distinction between this filing for PharmAthene, Inc. and the user's metadata reference to Altimmune, Inc.